Objective: Antiplatelet therapy is a class I indication in perioperative care after coronary artery bypass grafting to prevent graft occlusion. We sought to determine whether continuation of aspirin until surgery day suppresses platelet activity in the early period after off-pump coronary artery bypass grafting (OPCAB). Material and methods: Forty-two patients at mean age of 62.5 (AE7.9) years were included. Average risk rate (EuroScore logistic) was 2.2 (AE1.7) %. In all patients collagen/epinephrine stimulated platelet plug formation (closure time, CT) (CEPI-CT, s) using a platelet function analyzer (PFA-100), troponin I (TnI), creatine kinase-MB (CK-MB), ST segment elevation were evaluated a day before surgery, 4 h after chest closure, 24 and 120 h after surgery. Results: Preoperative mean CEPI-CTwas 224.8 (AE79.7) s. In 13 (30%) patients aspirin resistance (CEPI-CT < 163 s.) was observed. In 4, 24 and 120 h time points CEPI-CTwas significantly reduced: 164.4 (AE79), 168.5 (AE83.3) and 167.5 (AE80.4), respectively ( p < 0,001). TnI and CK-MB (ng/ml) levels raised in respective time points: 4 h (0.26 range 4; 1.9 range 6), 24 h (0.2 range 6; 2.6 range 8), 120 h (0.04 range 2; 0.6 range 5). ST segment elevation (mV) changed in time: 4 h (0.7 range 3.5), 48 h (0.7 range 2.8) and 120 h after surgery (0.2 range 1.5). There were no significant correlations between CEPI-CTand TnI, CK-MB, STsegment elevation found. Conclusion: Aspirin therapy continued until surgery day does not protect against acute platelet activation in patients after OPCAB. #
Introduction
Coronary artery bypass grafting (CABG) is a standard treatment for patients with multivessel coronary artery disease (CAD). Early-and long-term results also depend on pharmacological secondary prevention of CAD. Antiplatelet therapy is a class I indication in perioperative care after CABG to prevent graft occlusion [1] . Increased use of offpump CABG (OPCAB) resulted in an evidence-based consensus that OPCAB technique may effect a decrease in perioperative complications and shorten the length of hospitalization [2] . However, some studies reported lower patency of grafts and procoagulative modulation in comparison to on-pump CABG [3, 4] . Surgical intervention with no use of cardiopulmonary bypass may potentially increase the risk of platelet activation and thrombosis. The primary aim of this study was to describe platelet activation profile in the early postoperative days after OPCAB in patients on aspirin (ASA) therapy. The secondary aim was to evaluate the effect of high dose of aspirin on platelet function administered in second postoperative day (POD).
Methods
There were 42 patients at mean age of 62.5 (AE7.9) years prospectively included. Preoperative characteristics are presented in Table 1 . Patients were qualified according to class IA indications for CABG in stable coronary artery disease. Inclusion criteria were: age between 40 and 80 years old, elective CABG, preoperative ASA (75 mg/day), statin, beta-blocker, angiotensin convertaze inhibitor therapy or logistic EuroScore below 8%. Patients with a history of hematological disorders, transfusion less than 4 months before surgery, thrombolysis or platelet glycoprotein IIb/IIIa antagonists treatment in last 4 weeks, acute coronary syndrome in less than 3 weeks, perioperative mechanical circulatory support or cardiac arrest during surgical procedure were excluded. Study was approved by the local ethical committee and research was conducted according to principles of Declaration of Helsinki. All patients signed informed consent.
Operative technique
Anesthesia was induced using propofol 1-2 mg/kg, pancuronium 0.1 mg/kg and fentanyl 10 mg/kg, and was maintained by air/oxygen and propofol 3 mg/kg/h. Normothermia was maintained by using warm intravenous fluids, a heating mattress and with maintaining a warm operating theatre. Medium sternotomy was used to expose the heart. Left internal thoracic artery harvested in the pedicle manner was used in all cases. When grafting on the lateral wall was planned then the right pleural cavity was opened creating a place for heart rotation and vertical positioning with minimized homodynamic compression. One deep pericardial suture was placed at the posterior pericardium. Anticoagulation was achieved using 150 units/kg (not less than 100 mg) of heparin. The activated clotting time (ACT) was maintained above 250 s. The heart was stabilized with tissue stabilization system (Octopus 3 or Evolution Medtronic Inc., Minneapolis, MN). Coronary shunts were not used. When distal and proximal anastomoses were done protamine was administered in dose of 1:1 heparin-protamine ratio. Skinto-skin time and intraoperative blood loss were measured as well as adverse events.
Perioperative procedure
In the morning of surgery day all patients received 75 mg of ASA. After surgery patients were transferred to intensive care unit (ICU) on mechanical ventilation and, if hemodynamically stable with no signs of severe bleeding, anesthetic drugs were off. Mean mechanical ventilation time was 5.5 AE 1.7 h. If chest drainage did not exceed 100 ml per first 3 h heparin infusion was introduced to achieve ACT level between 140 and 160 s. On the 2nd postoperative day (POD) chest drainage was removed, 375 mg of ASA and 60-80 mg/ day of enoxaparin were introduced. During the following days 75 mg of ASA per day with enoxaparine were continued. Statin, beta-blocker and angiotensin convertaze inhibitor therapy started from 2nd POD.
Platelet activation and ischemia parameters assessment
A day before surgery, then 4-6, 24 and 120 h (5th POD) post-surgery, blood sampling and ECG parameters were collected. Platelet function was assessed using a platelet function analyzer (PFA-100, Dade Behring, Germany). This analyzer enables quantitative measurement (closure time, CT) of platelet-mediated hemostasis in uncoagulated (citrated) blood. The method simulates platelet activation by mechanical stress (shear stress), and also simulates contact of platelets with the collagen/epinephrine membrane. Detailed methodology used in our laboratory has been described elsewhere [5] . According to company data platelet function block is maintained with ASA when collagen/ epinephrine stimulated artificial capillary closure time (CEPI-CT) exceeds 163 s. Aspirin resistance was defined as CEPI-CT less than 163 s on ASA therapy minimum 7 days or lack of CEPI-CT prolongation with ASA high-dose (375 mg) followed by 75 mg per day. From same blood sample troponin I (TnI), creatine kinase-MB (CK-MB), complete coagulation times and blood cell count were evaluated. ST segment elevation was assessed using high frequency ECG. The highest absolute value from any ECG lead was recorded ( Fig. 1 ). SD -standard deviation, PCI -percutaneous coronary intervention, NT-pro-BNP -N-terminated brain natriuretic pro-peptide. normally distributed). Differences were considered significant at p < 0.05.
Statistical analysis

Results
There were no major complications (death, myocardial infarction, stroke, transient ischemic attack, reoperation) observed during procedure and postoperative course. Mean number of distal grafts was 2.9 (AE0.9) per patient. In 11 (26%) patients total arterial revascularization was performed. Mean skin-to-skin time was 129.4 (AE48.1) min with median intraoperative blood loss of 420 (range: 1400) ml. Postoperatively, transfusion of blood or plasma was necessary in 14 (33%) patients. In the whole group the average amount of transfusions was 1.3 (AE2.5) units per patient. Median ICU stay time was 1 (range: 4) day and in-hospital stay 10 (range: 2) days.
Platelet function
Preoperative mean CEPI-CT was 224.8 (AE79.7) s. In 13 (30%) patients preoperative aspirin resistance (CEPI-CT < 163 s) was observed. Postoperatively there was significant platelet activation observed (Graph 1), ( p < 0.001). Activation persisted till 5th POD. After 48 h when all patients received 375 mg of aspirin there was no significant platelet block found, mean CT-EPI 168.5 (AE83.3) versus 167.5 (AE80.4) s, after 24 and 120 h, respectively ( p = 0.55). In aspirin resistant patients no impact of OPCAB on platelet activation (CT-EPI) was observed, respectively: 119.9 (AE17.1 s, preoperatively), 129.9 (AE68 s, after 4 h), 120.3 (AE60.8 s, after 24 h) and 148.2 (AE80.8 s, after 120 h), ( p > 0.05). In aspirin responders significant CT-EPI reduction was found in the following time points: preoperatively (277.3 AE 30.7 s), after 4 h (181.7 AE 79.8 s; p < 0.001), after 24 h (189.7 AE 83.9 s) and after 120 h (177.1 AE 80.2 s). In aspirin responders higher chest drainage occurred in first 24 h (724.3; AE201 ml) compared to aspirin resistant patients (583.7 AE 83 ml), ( p = 0.02). Aspirin resistant patients needed significantly less transfusions (average per patient: 0.3 AE 0.9 units) in comparison to aspirin responders group (average per patient: 1.7 AE 2.9 units), p = 0.08.
Ischemia markers
Dynamic of mean TnI and ST segment elevations are presented in Table 2 . There were no significant correlations between CT-EPI changes and ischemia markers found. No significant differences were observed between aspirin resistant and responders groups in terms of TnI, CK-MB, and ST segment elevation dynamics (Table 3) . Hemoglobin concentration and hematocrit levels in certain time points did not differ significantly between the groups (Table 4) . However, aspirin resistant patients tended to achieve higher hemoglobin concentration 120 h post-surgery: 12.1 AE 1.1 versus 11.6 AE 1.2 g/dl (in aspirin responders group), p = 0.06.
Discussion
The presented study inspires discussion in three clinical areas: goal and effectiveness of antiplatelet therapy continued until surgery day before OPCAB, review of perioperative antiplatelet strategy in OPCAB patients and clinical implications for early-and long-term secondary prophylaxis of ischemic events after off-pump surgical revascularization.
Current guidelines on surgical treatment of coronary heart disease advise cessation of platelet inhibitors before CABG; 7 days for aspirin and 5 days for clopidogrel [1] . This is mainly based on trials which indicated higher postoperative drainage, more frequent revisions due to bleeding, increased transfusions and a higher incidence of wound healing complications when aspirin therapy was continued [6, 7] . However, lately Sun et al. in their meta-analysis have shown that those trials were mainly conducted on patients operated with use of cardiopulmonary bypass and with high aspirin doses administered preoperatively [8] . More recent publications revealed no impact of aspirin on bleeding and transfusions, especially when lower doses were used [9, 10] . The predominant goal of platelet blocking before surgical revascularization (both for OPCAB and on-pump CABG) is myocardial perfusion protection during surgery and early postoperative period. Gerrah et al. demonstrated that preoperative use of aspirin supported better oxygenation during and after CABG [11, 12] . In our cohort there was no significant difference between ASA resistant patients and ASA responders in terms of ischemia markers level during the postoperative observation period. It seems that OPCAB activates platelets in the ASA responders group, so no difference of CT-EPI and ischemia markers occurs between two groups. Few projects revealed a tendency towards better graft function with clinical benefit in mortality when aspirin was continued until surgery day. Increased bleeding was in fact reported but had no impact on hard clinical end points [9] . In relation to our results unequivocal conclusions of published projects may result from not taking under consideration preoperative aspirin resistance and acute platelet reaction on surgical interventions. We observed that in some patients aspirin protection may be suppressed with OPCAB. Clopidogrel-based pretreatment strategy was considered in latest studies. Data collected in unstable patients (NSTEMI/UA) referred to CABG showed a higher incidence of bleeding and reoperations when clopidogrel therapy was not stopped more than 5 days before surgery [13, 14] . On the other hand, a study performed by Karabulut et al. conducted on elective patients did not confirm such results, while 44% of patients received only 75 mg of clopidogrel and 50% of patients received aspirin with clopidogrel pretreatment [15] . Leong et al. divided a large group both in terms of use of CPB and clopidogrel pretreatment. There was no difference in bleeding in the OPCAB group (clopidogrel vs non-clopidogrel group) and nonclopidogrel patients operated with use of CPB had higher chest drainage than patients in the clopidogrel-OPCAB group [16] . One of the evidence-based advantages of OPCAB in comparison to on-pump technique is the reduction of bleeding and less need for transfusion [2, 3, 17] . Extracorporeal circulation impairs coagulation system by damaging plasma factors and platelets [18] . In OPCAB the coagulation system remains undamaged. Moreover, while in OPCAB intraoperative blood loss is decreased, the same quantity of procoagulative inductors (tissue factor) are exposed in systemic and coronary circulation [5] . Since our results show acute activation of preoperatively inhibited platelets, intraoperative and early myocardial protection strategy may be reconsidered. Perioperative heparin-protamine regime seems to be crucial if antiplatelet agents fail to safely and effectively block platelet activation in future OPCAB trials [19, 20] .
Procoagulative capability after OPCAB may persist for weeks and determine the risk for early graft failure or coronary events [21] . For years early aspirin therapy post-CABG is a class I indication to prevent vein grafts occlusion [1] . However, some studies reported that antiplatelet therapy does not have such impact on internal thoracic artery grafts [22] . As our study showed OPCAB may induce aspirin resistance. Compiling our data with other initial reports showed that aspirin resistance after CABG may persist for weeks and we have to face this oncoming clinical problem. In addition, the number of patients with genetically determined aspirin resistance may reach up to 30%. Larger studies proved a clinical impact of aspirin resistance on worse outcomes in primary prophylaxis in stable ischemic heart disease [23] . Those data support the rationale for looking for better antiplatelet medication than aspirin in patients who underwent OPCAB. First trials comparing clopidogrel with aspirin showed possible superiority of clopidogrel in terms of event free mid-term survival with the same safety level [24, 25] . An important limitation affecting methodology of this and other studies is a lack of general aspirin resistance definition. No single test can definitely demonstrate aspirin resistance. In clinical issues, aspirin resistance is considered when thrombosis occurs on aspirin therapy. In the laboratory, aspirin resistance may be identified as lack of arachidonic acid metabolism block, thromboxane production or present epinephrine stimulated platelet aggregation.
Conclusions
Aspirin therapy continued until surgery day does not protect against acute platelet activation in patients after OPCAB. Platelet activation persists for a minimum of 5 days after OPCAB. OPCAB may induce aspirin resistance. Since acute platelet activation occurs in aspirin responders preoperative aspirin therapy may have no impact on the perioperative ischemia markers level. 
